Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Amortizatization of Intangibles: 2021-2025

Historic Amortizatization of Intangibles for ARS Pharmaceuticals (SPRY) over the last 3 years, with Sep 2025 value amounting to $1.1 million.

  • ARS Pharmaceuticals' Amortizatization of Intangibles fell 40.20% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.2 million, marking a year-over-year decrease of 205.00%. This contributed to the annual value of -$7.3 million for FY2024, which is 5.93% down from last year.
  • ARS Pharmaceuticals' Amortizatization of Intangibles amounted to $1.1 million in Q3 2025, which was up 108.42% from -$13.0 million recorded in Q4 2024.
  • Over the past 5 years, ARS Pharmaceuticals' Amortizatization of Intangibles peaked at $5.9 million during Q2 2024, and registered a low of -$13.0 million during Q4 2024.
  • Its 3-year average for Amortizatization of Intangibles is -$1.4 million, with a median of -$1.7 million in 2023.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Amortizatization of Intangibles slumped by 705.96% in 2023, and later spiked by 434.70% in 2024.
  • Quarterly analysis of 5 years shows ARS Pharmaceuticals' Amortizatization of Intangibles stood at $243,000 in 2021, then climbed by 17.28% to $285,000 in 2022, then crashed by 705.96% to -$1.7 million in 2023, then plummeted by 650.67% to -$13.0 million in 2024, then plummeted by 40.20% to $1.1 million in 2025.
  • Its Amortizatization of Intangibles stands at $1.1 million for Q3 2025, versus -$13.0 million for Q4 2024 and $1.8 million for Q3 2024.